Flash Finance

Nephrocare Health Services LimitedNEPHROPLUSCorporate

Healthcare Service Provider Latest results: Jun 2026 6 quarters of data
Consolidated Standalone
₹614.35
MCap ₹6,178 Cr · P/E 72.7
Nephrocare Health Services Limited — Stock analysis & AI research Nephrocare Health Services Limited — Multibagger AI analysis Nephrocare Health Services Limited — Seasonality — best & worst months Nephrocare Health Services Limited — Technical indicators & charts Nephrocare Health Services Limited — Technical setup — score, trend, support & resistance Nephrocare Health Services Limited — Live exchange announcements
📋 Stocks With Strong Quarterly Results 📈 RSI Oversold Stocks 🏭 Healthcare sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹282 Cr
Sales · Jun 2026
+23.6% YoY
₹64 Cr
Operating Profit · Jun 2026
+33.1% YoY
22.7%
OPM % · Jun 2026
+7.6% YoY
₹32 Cr
Net Profit · Jun 2026
+33.2% YoY
₹3.19
EPS · Jun 2026
-75.6% YoY

📝 Nephrocare Health Services Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Nephrocare Health Services Limited reported revenue of ₹282 crore for the quarter ended June 2026 (Q1 FY27), up 23.6% from ₹228 crore in the same quarter last year, and up 5.9% sequentially over the March 2026 quarter.

Net profit rose 33.2% year-on-year to ₹32 crore, from ₹24 crore. Earnings per share (EPS) came in at ₹3.19.

Operating profit stood at ₹64 crore — an operating margin (OPM) of 22.7%, compared with 21.1% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Nephrocare Health Services Limited posted revenue of ₹1,000 crore, with a net profit of ₹77 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹1,054 crore with a net profit of ₹85 crore.

Valuation snapshot

At the current price of ₹614.35, NEPHROPLUS has a market capitalisation of ₹6,178 crore and a trailing P/E of about 72.7.

Within the Healthcare Service Provider industry, it is the largest of the 20 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 58.31%, foreign institutional investors (FIIs) 11.73%, domestic institutional investors (DIIs) 8.11%, public shareholders 21.85% of Nephrocare Health Services Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹6,178 Cr
Current Price ?
₹614.4
P/E ?
72.70above ind
Industry P/E ?
22.50
P/B ?
N/A
P/S ?
5.86
P/FCF ?
N/A
Enterprise Value ?
N/A
EV/EBITDA ?
N/A
PEG ?
N/A
Earnings Yield ?
1.4%
Dividend Yield ?
N/A
Profitability & Returns
Sales (TTM) ?
₹1,054 Cr
OPM ?
22.8%
Profit after tax (TTM) ?
₹85 Cr
EPS (TTM) ?
₹8.45
ROCE ?
N/A
ROE ?
N/A
ROA ?
N/A
Growth
Sales — latest qtr ?
₹282 Cr
PAT — latest qtr ?
₹32 Cr
YoY qtr sales growth ?
23.6%
YoY qtr profit growth ?
33.2%
Sales growth (3y) ?
N/A
Sales growth (5y) ?
N/A
Profit growth (3y) ?
N/A
Profit growth (5y) ?
N/A
Financial Health
Debt ?
N/A
Debt to Equity ?
N/A
Interest Coverage ?
2.2
Current Ratio ?
N/A
Ownership
Promoter holding ?
58.31%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
-3.4%
Return 6 months ?
4.9%

🗓️ Quarterly results (6 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 219228246260266282 +23.6% +5.9%
Operating Profit 514864615164 +33.1% +25.3%
Other Income 4743127 +6.6% -37.8%
Interest 6645632 -63.2% -26.5%
Depreciation 192023222625 +22.7% -5.6%
Profit Before Tax 3029-1363341 +41.5% +24.3%
Net Profit 2524-9323032 +33.2% +6.6%
EPS 119.3013.10-5.243.213.033.19 -75.6% +5.3%
OPM % 23.3% 21.1% 26.0% 23.5% 19.2% 22.7% +7.6% +18.2%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric Prev FY FY26 TTM YoY %
Sales — ₹1,000 Cr ₹1,054 Cr —
Operating Profit — ₹224 Cr ₹240 Cr —
OPM % — 22.40% 22.76% —
NPM % — 7.70% 8.06% —
Other Income — ₹26 Cr ₹26 Cr —
Depreciation — ₹91 Cr ₹96 Cr —
Interest — ₹60 Cr ₹56 Cr —
EBIT — ₹133 Cr ₹144 Cr —
PBT — ₹97 Cr ₹109 Cr —
Tax — — ₹9 Cr —
Net Profit — ₹77 Cr ₹85 Cr —
EPS — ₹14.10 ₹4.19 —
Material Cost — — ₹62 Cr —
Employee Cost — — ₹48 Cr —
Extraordinary Items — — — —

👥 Shareholding (latest 1 periods)

Metric Sep 2026 % Chg
Promoters 58.31% —
FIIs 11.73% —
DIIs 8.11% —
Public 21.85% —
No. of Shareholders 56,735 —

⚖️ Peer comparison

Industry: Healthcare Service Provider · 20 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 NEPHROPLUS Nephrocare Health ₹673.00 6,768 78.9 1,054 85 22.8% 8.1% — — 23.6% 33.2%
2 532067 3B BlackBio ₹1,205.90 1,166 18.8 153 56 34.9% 36.7% 47.1% 25.7% 50.7% -29.0%
3 514330 One Global ₹139.00 1,043 3.7 513 74 19.1% 14.5% 311.6% 288.9% 16.8% 43.0%
4 HEALTHX Health X ₹306.95 976 — 0 -1 -390.4% -376.2% — — -20.0% -367.5%
5 526546 Choksi Laboratories ₹61.93 146 19.9 47 2 26.8% 4.6% 10.1% 28.8% 7.5% 49.3%
6 540788 Aspira Pathlab ₹31.00 107 — 26 -0 3.8% -1.7% 13.5% -97.1% 17.5% -108.5%
7 530897 NG Industries ₹165.30 39 28.7 17 2 11.1% 11.4% -0.9% -77.7% 13.8% 104.3%
8 524602 Bandaram Pharma ₹30.99 33 162.8 79 1 4.8% 1.5% 70.2% -46.9% 195.7% 3322.0%
9 524548 Sharma East ₹50.09 32 13.9 37 1 9.6% 3.2% 20.3% 0.0% 13.7% -18.7%
10 542248 Deccan Health ₹35.53 30 34.8 82 3 6.4% 3.1% 9.1% 115.7% -0.3% 21.3%
11 539267 Samsrita Labs ₹17.13 28 — — — — — — — — —
12 523489 Chennai Meenakshi ₹34.47 28 — 37 -0 1.5% -1.1% 6.4% 16.1% -0.7% 100.4%
13 539428 Tejnaksh Healthcare ₹23.46 27 38.5 11 1 26.5% 11.3% -16.3% -47.5% 0.5% 24.1%
14 526139 Transgene Biotek ₹9.56 21 — 0 -2 -223.0% -766.2% -25.9% -146.3% 20.0% 9.5%
15 516110 Family Care ₹7.44 11 — 0 -8 -1321.3% -3505.7% -97.3% 80.3% 150.0% 39.5%
16 534422 Looks Health ₹5.73 10 177.4 0 0 41.2% 7.5% -2.6% 0.0% 75.7% —
17 531043 Dhanvantri Jeevan ₹19.95 10 16.1 28 1 3.2% 1.8% 14.2% -23.5% 41.6% 200.0%
18 526504 Dolphin Medical ₹1.85 10 5.2 1 0 13.0% 7.4% -2.6% 333.3% 21.2% -40.7%
19 541299 Dr Lalchandani ₹27.60 7 345.0 4 0 9.3% 1.7% — — -8.6% -148.1%
20 526187 Ashram Online.Com ₹6.29 7 — 1 -0 -74.9% -20.3% 33.3% -71.4% 31.6% 40.2%
❓ Frequently asked questions
What was Nephrocare Health Services Limited's revenue in Q1 FY27?
Nephrocare Health Services Limited reported revenue of ₹282 crore for the quarter ended June 2026 (Q1 FY27), up 23.6% from ₹228 crore in the same quarter last year, and up 5.9% sequentially over the March 2026 quarter.
What was Nephrocare Health Services Limited's net profit in Q1 FY27?
Net profit rose 33.2% year-on-year to ₹32 crore, from ₹24 crore. Earnings per share (EPS) came in at ₹3.19.
What is NEPHROPLUS's market capitalisation and P/E ratio?
At the current price of ₹614.35, NEPHROPLUS has a market capitalisation of ₹6,178 crore and a trailing P/E of about 72.7.
Who owns Nephrocare Health Services Limited? (shareholding pattern)
As of Sep 2026, promoters held 58.31%, foreign institutional investors (FIIs) 11.73%, domestic institutional investors (DIIs) 8.11%, public shareholders 21.85% of Nephrocare Health Services Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI